Physician profile
Robert J Morgan
NPI 1265867600
$4,994.42
in general payments reported to CMS, 2019-2025
38 companies · $1,458 in 2025
The $1,458 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $83.44 · 2020: $56.28 · 2021: $128 · 2022: $642 · 2023: $1,278 · 2024: $1,348 · 2025: $1,458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,995 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,994.81 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $686.79 | 2022-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $556.78 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $493.30 | 2021-2025 | |
| Exact Sciences Corporation | $335.56 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $276.00 | 2023-2025 | Gemtesa, Myfembree |
| Radius Health, INC. | $248.39 | 2023-2025 | Tymlos |
| Astrazeneca Pharmaceuticals LP | $246.69 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Otsuka America Pharmaceutical, INC. | $239.41 | 2023-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $192.27 | 2022-2025 | |
| Novo Nordisk INC | $183.24 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $154.96 | 2023-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $112.72 | 2021-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.44 | 2022-2025 | Xifaxan |
| Astellas Pharma US INC | $109.52 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $98.73 | 2024-2025 | Voquezna |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.